中国循证心血管医学杂志
中國循證心血管醫學雜誌
중국순증심혈관의학잡지
CHINESE JOURNAL OF EVIDENCE-BASES CARDIOVASCULAR MEDICINE
2014年
6期
758-759
,共2页
心血管疾病%焦虑抑郁症状%黛力新%多虑平%联合治疗%临床研究
心血管疾病%焦慮抑鬱癥狀%黛力新%多慮平%聯閤治療%臨床研究
심혈관질병%초필억욱증상%대력신%다필평%연합치료%림상연구
Cardiovascular diseases%Anxiety and depression symptoms%Deanxit%Doxepin%Combination therapy%Clinical study
目的：应用黛力新和多虑平联合治疗心血管疾病焦虑抑郁症状的患者，研究其疗效。方法入选解放军251医院心内科2013年1~3月的高血压和冠心病焦虑抑郁患者80例。随机分为2组，对照组和治疗组，每组各40例。在常规心血管疾病治疗的基础上，治疗组加服黛力新和多虑平，对照组单纯使用治疗心血管疾病的药物和多虑平或/和苯二氮卓类药物。疗程均为6周，评价临床疗效和不良反应，同时应用汉密尔顿抑郁量表（Hamilton depression scale，HAMD）于治疗前、治疗第6周测评。结果与对照组比较，治疗组无效率降低（25.0%vs.10.0%），差异具有统计学意义（P＜0.05）。对照组基本控制20.0%，显效27.5%，有效27.5%，治疗组分别为38.0%，25%，27%。与治疗前比较，治疗组治疗6周后睡眠障碍、迟滞、绝望感三种因子的评分均降低，差异具有统计学意义（P均＜0.05）。与对照组比较，治疗组睡眠障碍、迟滞、绝望感三种因子的评分均降低，差异具有统计学意义（P均＜0.05）。治疗组2周后出现口干3例，乏力3例，食欲减退3例，腹胀便秘2例，头昏2例，困倦2例。结论黛力新联合多虑平治疗心血管疾病焦虑抑郁症状疗效确切，安全性欠佳。
目的：應用黛力新和多慮平聯閤治療心血管疾病焦慮抑鬱癥狀的患者，研究其療效。方法入選解放軍251醫院心內科2013年1~3月的高血壓和冠心病焦慮抑鬱患者80例。隨機分為2組，對照組和治療組，每組各40例。在常規心血管疾病治療的基礎上，治療組加服黛力新和多慮平，對照組單純使用治療心血管疾病的藥物和多慮平或/和苯二氮卓類藥物。療程均為6週，評價臨床療效和不良反應，同時應用漢密爾頓抑鬱量錶（Hamilton depression scale，HAMD）于治療前、治療第6週測評。結果與對照組比較，治療組無效率降低（25.0%vs.10.0%），差異具有統計學意義（P＜0.05）。對照組基本控製20.0%，顯效27.5%，有效27.5%，治療組分彆為38.0%，25%，27%。與治療前比較，治療組治療6週後睡眠障礙、遲滯、絕望感三種因子的評分均降低，差異具有統計學意義（P均＜0.05）。與對照組比較，治療組睡眠障礙、遲滯、絕望感三種因子的評分均降低，差異具有統計學意義（P均＜0.05）。治療組2週後齣現口榦3例，乏力3例，食欲減退3例，腹脹便祕2例，頭昏2例，睏倦2例。結論黛力新聯閤多慮平治療心血管疾病焦慮抑鬱癥狀療效確切，安全性欠佳。
목적：응용대력신화다필평연합치료심혈관질병초필억욱증상적환자，연구기료효。방법입선해방군251의원심내과2013년1~3월적고혈압화관심병초필억욱환자80례。수궤분위2조，대조조화치료조，매조각40례。재상규심혈관질병치료적기출상，치료조가복대력신화다필평，대조조단순사용치료심혈관질병적약물화다필평혹/화분이담탁류약물。료정균위6주，평개림상료효화불량반응，동시응용한밀이돈억욱량표（Hamilton depression scale，HAMD）우치료전、치료제6주측평。결과여대조조비교，치료조무효솔강저（25.0%vs.10.0%），차이구유통계학의의（P＜0.05）。대조조기본공제20.0%，현효27.5%，유효27.5%，치료조분별위38.0%，25%，27%。여치료전비교，치료조치료6주후수면장애、지체、절망감삼충인자적평분균강저，차이구유통계학의의（P균＜0.05）。여대조조비교，치료조수면장애、지체、절망감삼충인자적평분균강저，차이구유통계학의의（P균＜0.05）。치료조2주후출현구간3례，핍력3례，식욕감퇴3례，복창편비2례，두혼2례，곤권2례。결론대력신연합다필평치료심혈관질병초필억욱증상료효학절，안전성흠가。
Objective To study the curative effect of deanxit combining doxepin on anxiety and depression symptoms in patients with cardiovascular diseases.Methods The patients (n=80) were chosen from Jan. 2013 to Mar. 2013 and divided randomly into control group and treatment group (eachn=40). The treatment group was given deanxit combining doxepin based on the routine therapy for cardiovascular diseases and control group was only given drugs for cardiovascular diseases and doxepin and/or benzodiazepine for 6 w. The curative effect and adverse reactions were reviewed, and Hamilton Depression Scale (HAMD) was used to detect patients before treatment and on the 6th w after treatment.Results Compared with control group, ineffective rate decreased (25.0%vs. 10.0%, P<0.05) in treatment group. The basic control rate was 20.0%, effectual rate was 27.5% and effective rate was 27.5% in control group, and 38.0%, 25% and 27% in treatment group. The scores of dyssomnia, retardation and hopelessness decreased in treatment group after treatment for 6 w (allP<0.05). Compared with control group the scores of dyssomnia, retardation and hopelessness decreased in treatment group (allP<0.05). In treatment group, there were 3 cases with dry mouth, 3 with fatigue, 3 with anorexia, 2 with abdominal distention and constipation, 2 with dizziness and 2 with tiredness.Conclusion Deanxit combining doxepin has definite curative effect on anxiety and depression symptoms of cardiovascular diseases, but safety is no ideal.
